Indian pharmaceutical company confirms 77.8% efficacy of Covaxin in third phase vaccination trial

Indian pharmaceutical company confirms 77.8% efficacy of Covaxin in third phase vaccination trial
# 03 July 2021 16:19 (UTC +04:00)

Bharat Biotech, an Indian pharmaceutical company, claimed that Covaxin was demonstrated to have 77.8% efficacy against COVID19 patients in the final analysis of the vaccine’s phase 3 clinical trials, APA reports citing Sputnik.

Bharat Biotech added that Covaxin also demonstrated 93.4% effectiveness against severe symptomatic Covid-19 cases.

#
#

THE OPERATION IS BEING PERFORMED